DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Bajorin DF. et al.
Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC).
J Clin Oncol 2017;
35: 4501-4501 (suppl; abstr 4501); oral presentation (DOI: 10.1200/JCO.2017.35.15_suppl.4501, no. 15_suppl [May 2017])
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.